Otsuka Holdings Co., Ltd. Stock

Equities

4578

JP3188220002

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-04-19 am EDT 5-day change 1st Jan Change
6,186 JPY -0.13% Intraday chart for Otsuka Holdings Co., Ltd. -3.13% +16.96%
Sales 2024 * 2,151B 13.93B Sales 2025 * 2,136B 13.83B Capitalization 3,361B 21.77B
Net income 2024 * 250B 1.62B Net income 2025 * 231B 1.5B EV / Sales 2024 * 1.34 x
Net cash position 2024 * 484B 3.13B Net cash position 2025 * 638B 4.13B EV / Sales 2025 * 1.28 x
P/E ratio 2024 *
13.4 x
P/E ratio 2025 *
14.2 x
Employees 34,388
Yield 2024 *
1.94%
Yield 2025 *
2.01%
Free-Float 81.41%
More Fundamentals * Assessed data
Dynamic Chart
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy MT
Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation MT
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia MT
Jefferies Adjusts Otsuka Holdings’ Price Target to 7,400 Yen From 6,800 Yen, Keeps at Buy MT
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical MT
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka DJ
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses MT
Otsuka Holdings Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending December 31, 2024 CI
Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending December 31, 2024 CI
Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024 CI
Otsuka Holdings Lowers 2023 Profit Outlook MT
Japan's Nikkei cruises to 34-year peak, briefly breaching 38,000 range RE
Japan's Nikkei soars to 34-year high on chip shares, earnings RE
Phase 3 Trial for Otsuka's Alzheimer's-related Agitation Treatment Fails to Meet Primary Endpoint MT
More news
1 day-0.13%
1 week-3.13%
Current month-1.97%
1 month-2.21%
3 months+6.84%
6 months+23.10%
Current year+16.96%
More quotes
1 week
6 066.00
Extreme 6066
6 391.00
1 month
6 066.00
Extreme 6066
6 510.00
Current year
5 030.00
Extreme 5030
6 510.00
1 year
4 412.00
Extreme 4412
6 510.00
3 years
3 827.00
Extreme 3827
6 510.00
5 years
3 224.00
Extreme 3224
6 510.00
10 years
2 842.00
Extreme 2842
6 510.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 08-07-07
Director of Finance/CFO 62 15-02-28
Chairman 59 08-07-07
Members of the board TitleAgeSince
Chief Executive Officer 73 08-07-07
Chairman 59 08-07-07
Director/Board Member 57 17-03-29
More insiders
Date Price Change Volume
24-04-19 6,186 -0.13% 1 008 800
24-04-18 6,194 -1.07% 777,700
24-04-17 6,261 -1.18% 643,400
24-04-16 6,336 -0.16% 921,200
24-04-15 6,346 -0.63% 688,400

Delayed Quote Japan Exchange, April 19, 2024 at 02:00 am EDT

More quotes
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements; - production of mineral waters, beverages and foods (2.1%); - other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc. Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%). Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
6,194 JPY
Average target price
5,982 JPY
Spread / Average Target
-3.43%
Consensus